Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease

Lu, Peng; Bi, Chongfeng; Deyu, Xia; Mao, Linling; Qian, Hongyan

doi:10.1016/j.msard.2019.02.009

Cited by 23 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suárez-Calvet M found that sTREM2 and CSF NFL levels were significant correlated with age in preclinical AD, AD dementia and the control group (11). The correlations between CSF sTREM2 and CSF NFL levels with age in syphilis/non-NS group were better than those in NS group, suggesting that microglial activation and neuronal injury in NS patients may obscure the effect of age on the CSF sTREM2 and CSF NFL levels (31).…”

Section: Figure 4 | Csf Levels Of Strem2 and Nfl In Ns Patients With mentioning

confidence: 99%

Increased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis

Chang

et al. 2020

Front. Neurol.

View full text Add to dashboard Cite

Objective: To explore cerebrospinal fluid (CSF) levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and neurofilament light proteins (NFL) in patients with neurosyphilis (NS). Methods: We enrolled 71 NS patients (41 early-NS and 30 late-NS patients) and 20 syphilis but non-NS patients whose CSF samples were collected. The CSF levels of the microglial activation biomarker sTREM2 and neuronal injury biomarker NFL were measured using ELISA. Results: CSF sTREM2 levels were significantly higher in NS patients compared to those in syphilis/non-NS patients (p < 0.001). In a subgroup analysis, the CSF sTREM2 levels elevated significantly in late-NS patients than those in early-NS patients (p < 0.001). The CSF sTREM2 levels in early-NS group were also significantly higher than those in syphilis/non-NS group (p = 0.024). Like CSF sTREM2, similar differences between groups were also found in CSF NFL. There was a moderate correlation between CSF sTREM2 and CSF NFL (r = 0.406, p < 0.001) in NS group. Conclusions: CSF sTREM2 levels elevated in NS and peaked at the late stage, suggesting that CSF sTREM2 may be a useful marker to quantify microglia activation in NS and may play a role in the progression of NS. The positive correlation between CSF sTREM2 and CSF NFL indicates a linkage between microglial activation and neuronal injury in NS.

show abstract

Section: Figure 4 | Csf Levels Of Strem2 and Nfl In Ns Patients With mentioning

confidence: 99%

Increased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis

Chang

et al. 2020

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Most surveys failed to identify any correlation between CSF and serum NfL and age in MS [ 261 , 264 , 266 , 272 , 284 ]. Some assessments examining NfL levels in MS compared to HCs found no correlation between age and CSF NfL in MS, but strengthened the association mentioned above with age in HCs [ 274 , 285 , 286 ]. On the other hand, different studies documented a significant relationship between age and CSF, serum, and plasma NfL in MS [ 40 , 156 , 278 , 287 ].…”

Section: Fluid Biomarkers Of Multiple Sclerosismentioning

confidence: 74%

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

Biernacki

Kokas

Sandi

et al. 2022

IJMS

View full text Add to dashboard Cite

Introduction: Multiple Sclerosis (MS) is the most common immune-mediated chronic neurodegenerative disease of the central nervous system (CNS) affecting young people. This is due to the permanent disability, cognitive impairment, and the enormous detrimental impact MS can exert on a patient’s health-related quality of life. It is of great importance to recognise it in time and commence adequate treatment at an early stage. The currently used disease-modifying therapies (DMT) aim to reduce disease activity and thus halt disability development, which in current clinical practice are monitored by clinical and imaging parameters but not by biomarkers found in blood and/or the cerebrospinal fluid (CSF). Both clinical and radiological measures routinely used to monitor disease activity lack information on the fundamental pathophysiological features and mechanisms of MS. Furthermore, they lag behind the disease process itself. By the time a clinical relapse becomes evident or a new lesion appears on the MRI scan, potentially irreversible damage has already occurred in the CNS. In recent years, several biomarkers that previously have been linked to other neurological and immunological diseases have received increased attention in MS. Additionally, other novel, potential biomarkers with prognostic and diagnostic properties have been detected in the CSF and blood of MS patients. Areas covered: In this review, we summarise the most up-to-date knowledge and research conducted on the already known and most promising new biomarker candidates found in the CSF and blood of MS patients. Discussion: the current diagnostic criteria of MS relies on three pillars: MRI imaging, clinical events, and the presence of oligoclonal bands in the CSF (which was reinstated into the diagnostic criteria by the most recent revision). Even though the most recent McDonald criteria made the diagnosis of MS faster than the prior iteration, it is still not an infallible diagnostic toolset, especially at the very early stage of the clinically isolated syndrome. Together with the gold standard MRI and clinical measures, ancillary blood and CSF biomarkers may not just improve diagnostic accuracy and speed but very well may become agents to monitor therapeutic efficacy and make even more personalised treatment in MS a reality in the near future. The major disadvantage of these biomarkers in the past has been the need to obtain CSF to measure them. However, the recent advances in extremely sensitive immunoassays made their measurement possible from peripheral blood even when present only in minuscule concentrations. This should mark the beginning of a new biomarker research and utilisation era in MS.

show abstract

“…We noted an elevation of 2,640% of CSF concentrations of NfL over normative control values, potentially reflecting disease activity. Prior studies of inflammatory demyelinating diseases noted increased CSF NfL concentrations across various groups including clinically isolated syndrome (CIS; mean NfL: 15,138.50 pg/ml), NMOSD (mean: 15,400.00 pg/ml), and MS (mean: 5,789.50 pg/mL) ( 20 ). This study suggests no statistically significant association with classical biomarkers (OCB+/– in CIS and MS or AQP4 in NMOSD) and NfL concentrations but a potential relationship between CSF NfL level and disease activity represented by MRI contrast-enhancing lesions ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

“…Prior studies of inflammatory demyelinating diseases noted increased CSF NfL concentrations across various groups including clinically isolated syndrome (CIS; mean NfL: 15,138.50 pg/ml), NMOSD (mean: 15,400.00 pg/ml), and MS (mean: 5,789.50 pg/mL) ( 20 ). This study suggests no statistically significant association with classical biomarkers (OCB+/– in CIS and MS or AQP4 in NMOSD) and NfL concentrations but a potential relationship between CSF NfL level and disease activity represented by MRI contrast-enhancing lesions ( 20 ). Analogous associations in axonal injury biomarkers and imaging for traumatic brain injury (TBI) patients has also indicated potential clinical significance.…”

Section: Discussionmentioning

confidence: 99%

A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis

Mizenko¹,

Bennett

Owens³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Biomarkers are needed to guide therapeutic decision making in autoimmune and paraneoplastic neurologic disorders. Here, we describe a case of paraneoplastic collapsing response-mediator protein-5 (CRMP5)-associated transverse myelitis (TM) where plasma neurofilament light (NfL) chain and glial fibrillary protein (GFAP) levels were observed over a 14-month clinical course, correlating with radiographical and clinical outcome measures in response to treatment. Blood and CSF samples obtained at diagnosis as well as 7 and 14 months into treatment. At the time of initial diagnosis, both plasma NfL (782.62 pg/ml) and GFAP (283.26 pg/ml) were significantly elevated. Initial treatment was with IV steroids and plasma exchange (PLEX) followed by neuroendocrine tumor removal, chemotherapy, and radiation. After initial improvement with chemotherapy, the patient experienced clinical worsening and transient elevation of plasma NfL (103.27 pg/ml and GFAP (211.58 pg/ml) levels. Whole body positron emission tomography PET scan did not demonstrate recurrence of malignancy. Repeat PLEX and rituximab induction resulted in improvements in patient function, neurologic exam, and plasma biomarker levels. To our knowledge, this is the first described longitudinal, prospective analysis of neuronal injury biomarkers and association of clinical treatment outcomes in CRMP5 myelitis. Our findings suggest that clinical improvement correlates with NfL and GFAP concentrations.

show abstract

Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease

Cited by 23 publications

References 27 publications

Increased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis

Increased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis

Contact Info

Product

Resources

About